Pfizer

This study tests whether a fifth dose of Pfizer's Lyme disease vaccine (VLA15) is safe and boosts protection. It involves about 1,700 healthy people aged 7 and older who already received four doses. Participants get either the vaccine or a saltwater shot and are followed for 12 m…

This study tests whether a vaccine can prevent C. difficile infection, a severe diarrheal illness, in adults 65 and older. About 32,000 participants will receive either the vaccine or a placebo shot. The study will track infections and side effects for up to 3.5 years.

This study looks at whether giving a second RSV vaccine during a later pregnancy is safe and helps protect newborns. About 550 pregnant women who previously received the RSV vaccine will get another dose. Researchers will also check how long immunity lasts from the first dose by …

This study tests a vaccine given to pregnant women to protect their babies from group B streptococcus (GBS), a bacteria that can cause serious illness in newborns. About 6,000 healthy pregnant women will receive either the GBS vaccine or a placebo (saltwater shot). Researchers wi…

This study looks at how well a 20-valent pneumococcal vaccine works against pneumonia in adults aged 65 and older. Participants are hospitalized with suspected pneumonia and provide a urine sample to check for specific bacterial strains. Researchers compare vaccination rates betw…

This study is a post-marketing safety check for Prevenar 20, a vaccine that protects against pneumococcal disease. About 660 people in Korea, from infants 6 weeks old to adults, will receive one dose of the vaccine. Researchers will track any side effects for 28 days to make sure…

This study tests an experimental vaccine to protect against E. coli bacteria. It involves 310 healthy adults aged 18 to 64. The main goal is to check if the vaccine is safe and what side effects it may cause. Researchers will monitor reactions like pain, fever, and fatigue for up…

This study tests an experimental mRNA flu vaccine in healthy adults aged 18 and older. Researchers want to see if it is safe and triggers a strong immune response. Participants receive one shot and are followed for about 6 months with blood tests and a nasal swab. The results wil…

This study compares a targeted drug called inotuzumab ozogamicin to standard chemotherapy (ALLR3) for children aged 1 to 17 with high-risk relapsed B-cell acute lymphoblastic leukemia (ALL). The goal is to see if the new drug can better eliminate cancer cells after one round of t…

This program offers early access to ritlecitinib, an experimental pill, for people with severe alopecia areata who have lost at least half of their scalp hair and have not improved with standard treatments. The goal is to provide a potential treatment option before the drug is fu…

This study tests whether a new drug, PF-08634404, combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to receive either the n…

This study tests an experimental medicine called PF-07275315 for adults with moderate-to-severe asthma that is not well controlled. About 252 participants will receive either the study drug or a placebo as injections over 12 weeks. The goal is to see if the drug improves breathin…

This study tests a new medicine called marstacimab in people with severe hemophilia A who want to switch from their current preventive treatment (emicizumab). The goal is to see if marstacimab is safe and how the body handles it. About 15 teens and adults aged 12 to 75 will recei…

This study tracks how effective and safe the drug lorlatinib is for people with ALK-positive non-small cell lung cancer who haven't had treatment yet. Researchers will follow about 90 patients in France to see how long they live without the cancer growing and how well they respon…

This study looks at the long-term safety and effectiveness of a drug called marstacimab in people with severe hemophilia A or B. Participants receive regular injections to help prevent bleeding episodes. The goal is to see if this treatment can reduce bleeds and the need for othe…

This study looks at the long-term safety and effects of a medicine called PF-07868489 for people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lung arteries makes the heart work harder. It is for adults who completed an earlier study of …

This study is tracking 183 adults with moderate-to-severe eczema (atopic dermatitis) who take abrocitinib pills daily for up to 24 months. Researchers want to see how well the drug clears or nearly clears the skin in real-life conditions, not just in a lab. Participants can also …

This study follows 850 people with alopecia areata (a condition causing patchy or total hair loss) who are prescribed the drug ritlecitinib. Researchers will measure hair regrowth and other outcomes over 24 weeks in real-world clinics, not a controlled lab. The goal is to see how…

This study is testing the safety and how the body handles a combination of two medicines, aztreonam and avibactam (ATM-AVI), in newborns and infants up to 9 months old who are in the hospital with a suspected or confirmed infection caused by gram-negative bacteria. The study has …

This early-stage study tests a combination of two drugs, elranatamab (given as a shot) and iberdomide (taken by mouth), in people with multiple myeloma that has returned or stopped responding to prior treatments. The main goal is to check safety and find the right dose. About 87 …

This study tests a new medicine called PF-08634404 combined with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 550 participants who haven't had prior treatment for this stage will receive the drug combo or a stan…

This study tests a new medicine, PF-08634404, in adults with advanced bladder cancer that has spread. Some participants get the drug alone, others get it with another cancer drug. The goal is to see if the treatment is safe and shrinks tumors. About 132 people will take part.

This study tests whether adding a new drug (Sigvotatug Vedotin) to standard immunotherapy (pembrolizumab) helps people with advanced non-small cell lung cancer that has high PD-L1 levels. About 714 participants will receive either the combo or pembrolizumab alone. The goal is to …

This phase 3 study tests a new drug, PF-07248144, combined with fulvestrant for people with HR-positive, HER2-negative advanced or metastatic breast cancer that worsened after prior CDK4/6 inhibitor therapy. About 400 participants will be randomly assigned to receive either the n…

This study looks at the long-term safety and effects of a daily pill called ritlecitinib for people with severe alopecia areata, a condition causing major hair loss. It includes 140 people who already completed earlier studies on this drug. Participants will take the medicine onc…

This study tests an experimental drug called etrasimod in children aged 2 to 12 with moderate to severe ulcerative colitis. The goal is to see if the drug can safely reduce inflammation and help children reach remission. Participants will take the drug for up to 52 weeks, with an…

This study tests whether adding an experimental drug (PF-06821497) to standard treatment (enzalutamide) works better than enzalutamide alone for men with metastatic castration-resistant prostate cancer that hasn't been treated with certain other drugs. About 900 participants will…

This study tests an experimental medicine called PF-07275315 for people with moderate-to-severe COPD, a lung disease that makes breathing hard. About 1,156 adults aged 35 to 80 who have had at least two COPD flare-ups in the past year will receive either the study drug or a place…

This study tests an oral drug called etrasimod in adolescents aged 12 to 17 with moderate to severe ulcerative colitis, a chronic bowel condition causing inflammation and symptoms like diarrhea and pain. The goal is to see if the drug can safely reduce inflammation and help achie…

This study tests a new experimental drug, PF-07934040, for people with advanced solid tumors that have a KRAS gene mutation. The drug is taken as a pill twice a day, either alone or with other anti-cancer medicines given by IV. The goal is to find the safest dose and see if the d…

This study tests a new medicine called PF-08634404, given alone or with another drug (ipilimumab), for adults with advanced liver cancer that cannot be removed by surgery. The goal is to check safety and see if the treatment shrinks tumors. About 138 participants will receive the…

This study tests a new medicine, PF-08634404, combined with chemotherapy against the standard treatment (bevacizumab plus chemotherapy) in people with colorectal cancer that has spread. About 800 adults who have not had prior treatment for metastatic disease will be randomly assi…

This study tests a drug called disitamab vedotin in people with advanced breast cancer that has spread and is hard to treat. Participants must have tumors with a protein called HER2 and have tried other treatments before. The drug is given as an IV every two weeks to see if it ca…

This early-stage study tests a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors (like melanoma, lung, or colon cancer) that have a specific BRAF gene change and have stopped responding to standard treatments. The drug is given alone or combined w…

This study tracks the safety and effects of Litfulo in 3000 adults and teens (12+) with severe alopecia areata, a condition causing major hair loss. Researchers will monitor side effects and how well the drug regrows hair over 48 weeks. Participants must already be prescribed Lit…

This study tests a new antiviral drug, ibuzatrelvir, alone or combined with remdesivir, in adults with severely weakened immune systems who have mild-to-moderate COVID-19 symptoms. The goal is to see if these treatments can prevent hospitalization, emergency care, or worsening in…

This study is tracking the safety and effectiveness of the arthritis drug Xeljanz XR in about 200 people in Korea who have moderate to severe rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Participants take the drug as part of their normal care, and researc…

This study tests a new IV antibiotic (aztreonam-avibactam) in hospitalized children aged 9 months to 18 years with serious gram-negative bacterial infections. The goal is to see how the drug moves through the body, if it is safe, and how well it works compared to the best availab…

This study tests a new drug (PF-07220060) plus letrozole against standard treatments for people with HR-positive, HER2-negative advanced or metastatic breast cancer who haven't had prior therapy for advanced disease. About 1,020 adults will be randomly assigned to either the new …

This early-phase study tests an experimental drug called PF-08046876 in people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. The drug is designed to attach to cancer cells and kill them directly. The main goals are to check safety, find the ri…

This study looks at the safety and effectiveness of Xeljanz in children aged 2 to 17 with juvenile idiopathic arthritis or juvenile psoriatic arthritis. It is an observational study in Korean clinics, following each child for up to 44 weeks. The goal is to monitor side effects an…

This study tracks 1100 people with moderate to severe atopic dermatitis (a type of eczema) who are starting Cibinqo tablets. Researchers will record any side effects and measure how well the drug clears the rash over about a year. The goal is to confirm the medicine's safety and …

This study tests a new medicine called dazukibart for people with active dermatomyositis or polymyositis, rare diseases that cause muscle inflammation and weakness. About 318 adults will receive either the study drug or a placebo as an IV infusion every 4 weeks for 48 weeks. The …

This study follows 173 people with hemophilia A or B who already received a one-time gene therapy (giroctocogene fitelparvovec or fidanacogene elaparvovec) in earlier Pfizer trials. Researchers will monitor participants for years to check long-term safety, including blood clots, …

This study tests two doses (50 mg and 100 mg) of the daily pill ritlecitinib in people aged 12 and older with severe alopecia areata, a condition causing significant hair loss. About 550 participants will be randomly assigned to one of the two doses for about 13 months. The goal …

This study tests a new medicine, PF-08634404, for adults with advanced kidney cancer that has spread. The goal is to see if it is safe and can shrink tumors when used alone or with other cancer drugs. Participants will receive the medicine through an IV at a clinic. The trial is …

This study tests a new drug called elranatamab, alone or with another drug (daratumumab), in people whose multiple myeloma has returned after at least one prior treatment. About 944 participants will be randomly assigned to one of three treatment groups. The goal is to see if elr…

This early-stage study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…

This study tests if adding the experimental drug mevrometostat to standard enzalutamide therapy works better than enzalutamide alone for men with metastatic castration-sensitive prostate cancer (cancer that has spread but still responds to hormone therapy). About 1,000 participan…

This study tests a daily pill called ritlecitinib for people with moderate to severe hidradenitis suppurativa (HS), a condition causing painful red skin lumps. About 240 adults who haven't been helped by antibiotics will receive either the drug or a placebo for 16 weeks. Research…

This study tests a new experimental drug (PF-07799544) combined with another drug (PF-07799933) in adults with advanced solid tumors that have a specific gene change called BRAF V600. The goal is to see if the combination is safe and can shrink or control the cancer. Participants…

This study tests a daily pill called ritlecitinib for children aged 6 to 12 with severe alopecia areata, a condition causing significant hair loss. About 225 participants will receive either a high dose, low dose, or placebo for 6 months. The goal is to see if the medicine safely…

This study looks at the long-term safety of the drug dazukibart for people with dermatomyositis or polymyositis, rare diseases that cause muscle weakness and fatigue. About 211 participants who completed a previous dazukibart study will receive IV infusions every 4 weeks for abou…

This study tests the long-term safety and effectiveness of a daily liquid medicine called abrocitinib for children aged 2 and older with moderate-to-severe eczema. About 500 kids will take the drug for up to 24 months, with or without topical creams. The goal is to see if the dru…

This study tests a new medicine called marstacimab, given as a weekly shot under the skin, to prevent bleeding in children aged 1 to 17 with severe hemophilia A or B. Researchers will compare how well it works to the children's own past year of standard treatment. The goal is to …

This study tests an experimental pill called ibuzatrelvir in adults and teens with mild-to-moderate COVID-19 who are at high risk for severe illness. Participants take the pill or a placebo for 5 days at home. The goal is to see if the drug reduces emergency visits, hospitalizati…

This study is for people with chronic myeloid leukemia (CML) who are taking or will take the drug BOSULIF as part of their normal care. It will track 600 patients in Korea to see how safe and effective the drug is in real-world settings. All participants receive BOSULIF, and the …

This study is for adults in Korea who are newly diagnosed with a type of blood cancer called acute myeloid leukemia (AML) and are already receiving the drug Mylotarg as part of their regular care. The goal is to watch for side effects and see how the disease responds over time. N…

This study tests a new medicine called MET097, given as a weekly shot under the skin, to help adults who are overweight or have obesity and type 2 diabetes lose weight. About 1,000 people will take part; two-thirds get the real medicine and one-third get a placebo (fake shot). Th…

This study tests an experimental drug called PF-06835375 in adults with moderate to severe primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The drug is given as multiple injections under the skin. The main goal…

This study looks at how well the drug abrocitinib works for people with moderate-to-severe eczema (atopic dermatitis) who have already tried up to two biologic treatments without success or couldn't tolerate them. About 150 adults and teens aged 12 and older will take abrocitinib…

This early-stage study tests a new medicine, PF-08046033, in adults with advanced lung cancer, esophageal cancer, or melanoma that has spread or can't be removed. The main goals are to check safety, find the right dose, and see if it helps control the cancer. Participants receive…

This study tests an experimental drug (PF-07248144) in people with advanced breast, prostate, or lung cancer that has spread or no longer responds to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. About 320 participants will receive …

This study tests a new cancer pill (PF-08032562) in people with advanced breast or colorectal cancer that has spread. The goal is to find the safest and most effective dose, and to see how well it works alone or with other cancer treatments. About 260 adults will take the pill da…

This study tracks 360 adults aged 18-65 with moderate to severe ulcerative colitis who are prescribed etrasimod as part of their normal care. Researchers will measure symptom control, like fewer bowel movements and less bleeding, over 52 weeks using online health questionnaires. …

This study tests whether a new drug combination (elranatamab, daratumumab, and lenalidomide) works better than the current standard treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The new combo uses a targeted immune therapy to a…

This study tests two experimental drugs (PF-07275315 and PF-07264660) for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to skin creams. About 340 participants will receive the drugs or a placebo as injections over several months. The goal is…

This study tests a new medicine called PF-08634404 given with chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first to check safety and response, then to compare the new comb…

This study tests whether adding an experimental drug (PF-06821497) to a standard hormone therapy (enzalutamide) can slow or stop cancer growth better than current options (enzalutamide alone or chemo) in men with advanced prostate cancer that has spread and is no longer respondin…

This study follows 200 people aged 12 and older with moderate-to-severe eczema who are starting a new prescription of abrocitinib. Researchers will track how well the drug controls symptoms like itching and rash over 12 months in real-world settings. The goal is to see if the imp…

This study tests a new drug, PF-08046054, against the standard chemo docetaxel for people with advanced PD-L1 positive non-small cell lung cancer that has spread or can't be removed. About 680 adults whose cancer got worse after prior treatments will be randomly assigned to one o…

This program provides early access to the drug etrasimod for people with severe ulcerative colitis who have not responded to at least three other treatments. It is a compassionate-use option for those who have no other choices. The goal is to control the disease, not to cure it.

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive lung cancer. Participants must be 18 or older, have T-SCLC that hasn't been treated yet, and have had a prior EGFR-mutated…

This study tests a new medicine called PF-08634404 combined with other cancer drugs in people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The main goals are to check safety, side effects, and whether the combination can shrink tumors…

This study offers ongoing access to the drug elranatamab for people with multiple myeloma who were already benefiting from it in earlier Pfizer studies. About 80 participants will continue treatment and be monitored for side effects. The goal is to keep providing the drug while c…

This study tests a new medicine called elranatamab, given as a weekly shot, for people with multiple myeloma that has returned or stopped responding to prior treatments. About 492 adults will be split into two groups: one gets elranatamab alone, the other gets a standard combinat…

This study watches how well the drug etrasimod works for adults with moderate to severe ulcerative colitis in everyday medical practice. About 300 participants will take etrasimod as prescribed by their doctor and fill out symptom questionnaires on their phone or computer. The go…

This early-stage study is testing a new drug called PF-08052667 for adults with a specific type of bladder cancer that hasn't spread into the muscle. The goal is to find a safe dose and see if it helps control the cancer when used alone or combined with other treatments. The stud…

This study provides continued access to the cancer drugs encorafenib and/or binimetinib for patients who were already taking them in earlier clinical trials and are still benefiting. It allows these patients to keep receiving the same treatment for up to about 5 more years while …

This study is testing a new oral medication called osivelotor for people with sickle cell disease. The main goals are to see if the drug can safely increase hemoglobin levels and reduce the frequency of painful vaso-occlusive crises (VOCs). The trial will involve nearly 400 adult…

This study tests whether the drug rimegepant can prevent migraines in children and adolescents aged 6 to 18 who have frequent migraines. Participants will take either rimegepant or a placebo daily for 12 weeks. The goal is to see if the drug reduces the number of migraine days pe…

This study tests a dissolving tablet called rimegepant to prevent migraines in adolescents aged 12 to 17 who have chronic migraine (15+ headache days per month). About 200 teens will take either rimegepant or a placebo every other day for 3 months, then all will receive rimegepan…

This study tests whether the drug rimegepant can safely and effectively stop moderate to severe migraine headaches in children and adolescents aged 6 to 17. About 2,100 participants will receive either the drug or a placebo. The goal is to see if the drug helps them become pain-f…

This study is checking how safe a migraine medicine called rimegepant is for children and teenagers aged 6 to 18 when used over a long period. About 600 participants who have migraines will take the medicine as needed for acute attacks. The main goal is to track any side effects …

This study tests whether adding ponsegromab to standard chemotherapy can help adults with advanced pancreatic cancer who are experiencing severe weight loss and poor appetite (cachexia). About 982 participants will receive either ponsegromab or a placebo alongside their first che…

This study tests the safety of a single dose of zavegepant nasal spray in 16 children aged 6 to 12 who have had migraines for at least 6 months. The medicine is given as one spray into one nostril, and the dose depends on the child's weight. Researchers will monitor how the body …

This study tests a daily oral medication called ritlecitinib for adults with chronic spontaneous urticaria (CSU) — a condition causing itchy hives and deep skin swelling without a clear trigger. About 200 participants who haven't found relief from antihistamines will be randomly …

This study tests whether the medicine abrocitinib can safely improve moderate-to-severe eczema in children aged 6 to 12. About 150 kids will be randomly assigned to receive either abrocitinib or a placebo for 16 weeks. The main goals are to see if the medicine clears the skin and…

This study tests whether the drug rimegepant can prevent migraines that happen around a woman's period. About 723 women aged 18 to 45 with regular cycles and a history of menstrual migraines will take rimegepant or a placebo during the days leading up to and including their perio…

This study tests an experimental oral medicine (PF-07328948) in 620 adults with heart failure. Participants will be randomly assigned to receive the drug or a placebo for 36 weeks. The goal is to see if the drug improves walking distance, heart failure symptoms, and quality of li…

This early-stage study tests a new drug called PF-07832837 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. Researchers will also look for early signs that the drug might…

This study follows 120 people with ulcerative colitis who are already taking tofacitinib as part of their normal care. Researchers will look at registry data to see how well the drug controls symptoms and if patients stick with treatment. No new treatments or procedures are given…

This study observes the safety and effectiveness of Zavicefta, an antibiotic, in patients with complicated abdominal or urinary tract infections or hospital-acquired pneumonia. About 600 people aged 3 months and older will be followed after receiving the drug as part of normal ca…

This early-stage study tests how the body processes different doses of the experimental drug atirmociclib when taken with food. It involves 72 healthy adults aged 18-65. The goal is to measure drug levels in the blood and check safety, not to treat any disease.

This study watches children in India who are prescribed somatrogon for growth hormone deficiency. It aims to check for side effects over 3 years during routine care. About 50 children aged 3 and older will take part. The study does not require extra clinic visits and helps doctor…

This early-stage study in 16 healthy adults aims to see how a new version of the experimental drug PF-07799933 is absorbed by the body, especially when taken with a high-fat meal or with an acid-reducing drug. Participants will take single doses of the drug and provide blood samp…

This study follows 300 people under 21 who developed heart inflammation (myocarditis or pericarditis) within a week of receiving the COMIRNATY COVID-19 vaccine. Researchers will track their heart health for up to 5 years using imaging and tests to understand long-term effects. Th…

This study tracks 600 adults in Korea with ALK-positive metastatic non-small cell lung cancer who are taking the drug Lorviqua as part of their normal care. Researchers will record any side effects and measure how well the drug controls the cancer using standard tumor response cr…

This early-stage study tests a new medicine, PF-07985631, in healthy adults to see if it is safe and how the body processes it. The drug is being developed for a kidney disease called IgA nephropathy. Participants receive either the drug or a placebo as a single injection and are…

This early-stage study tests a new tablet form of the experimental COVID-19 drug ibuzatrelvir in 18 healthy adults. Researchers want to see how much of the drug gets into the blood with the new tablet compared to the original, and whether taking it with food or as a drink changes…

This early-stage study is testing a single dose of an experimental medicine called PF-08653944 in 54 overweight or obese adults. The goal is to see how the drug is absorbed when injected into the thigh, upper arm, or abdomen. Researchers will also monitor safety through blood tes…

This study will review medical records of 4,000 adults with ulcerative colitis to see which treatments doctors prescribe and how well they control inflammation. The goal is to create an updated treatment guide. No new drugs or procedures are tested; it is purely observational.

This study looks at how much of the medication etrasimod ends up in breast milk. About 8 healthy breastfeeding women will take a 2 mg pill daily for 7 days while staying at a clinic. They cannot nurse their babies during the study, so they need a backup feeding plan. Researchers …

This study looks at how different levels of liver function affect the way the body processes a study medicine called PF-07328948. Researchers will give a single tablet to 26 adults, some with liver problems and some healthy, and monitor them for about 6 days. The goal is to see i…

This early-stage study looks at how a new medicine, PF-08653944, changes the speed at which the stomach empties food in 20 adults who are overweight or have obesity. Participants take the medicine for a short time, and doctors measure stomach emptying and watch for side effects. …

This study tests whether a new tablet form of tafamidis works the same as the current capsule. About 24 healthy adults will take a single dose of each form under fed conditions. The main goal is to measure drug levels in the blood, not to treat any disease.

This study will look at medical records of 300 people in the US with severe alopecia areata who started taking ritlecitinib. Researchers want to see how well the drug works outside of clinical trials, especially in groups often left out of studies. The goal is to understand who g…

This study looks at how a new medicine called PF-07328948 is absorbed, spread, and removed from the body. It involves 8 healthy men aged 18 to 64. Participants take the drug by mouth and by injection, and provide blood, urine, and stool samples. The goal is to learn how the body …

This study looks at how the experimental drug PF-07328948 is handled by the body in people with normal or reduced kidney function. About 28 adults aged 18 to 80 will receive a single dose and be monitored for safety and drug levels. Results will help determine if kidney problems …

This study looks at how an experimental medicine, PF-08653944, is processed by the body and whether it is safe. About 26 adults with normal or impaired liver function will receive a single injection. Researchers will compare results across groups to guide future use in people wit…

This study looks at how the drug vepdegestrant is handled by the body in people with moderate to severe liver impairment compared to healthy volunteers. About 24 adults (ages 18-70) will take a single dose and stay at the clinic for 11 days for monitoring. The goal is to understa…

This study looks at anonymous health insurance records from Germany to learn more about a rare heart condition called ATTR-CM. Researchers want to see how long people live, how often they are hospitalized, and how common the disease is. No new treatments or tests are given—this i…

This study watches pregnant women with eczema who take the medicine CIBINQO (abrocitinib) and compares them to pregnant women with eczema who do not take it. Researchers want to see if the medicine causes birth defects or other health problems in babies. About 400 women will join…

This early-stage study tests a new medicine, PF-07985631, in healthy adults to see if it is safe and how the body handles it. The medicine is being developed for a kidney disease called IgA nephropathy. Participants receive either the drug or a placebo as an injection or IV, and …

This observational study follows pregnant women with migraine who have taken the drug rimegepant, comparing them to those who have not. Researchers will track health outcomes for mothers and babies, including birth defects and pregnancy complications, up to 12 months after birth.…

This study looks at how patients with metastatic breast cancer in Sweden are actually using the drug palbociclib in everyday medical practice. Researchers will track 1,500 adults who have filled a prescription for palbociclib to see how long they stay on treatment and how well th…

This study looks at possible eye-related side effects in people with cervical cancer that has returned or spread, who are being treated with the drug TIVDAK. About 100 participants will receive TIVDAK every three weeks and undergo regular eye exams before, during, and after treat…

This study aims to see if two different versions of a migraine medication work the same way in the body. Pfizer is recruiting 64 healthy adults to take both versions and compare how they're absorbed. The goal is to understand if a new formulation could be just as effective as the…